A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

BACKGROUND. The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohistochemistry expression as a biomarker of onartuzu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2016
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016069/
https://ncbi.nlm.nih.gov/pubmed/27401892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0038
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia